Analysis of results after the implementation of fast recovery protocols in hepatopancreatobiliary surgery

Análisis de resultados después de la implementación de protocolos de recuperación acelerada en cirugía hepatopancreatobiliar

Juan Pablo Aristizábal\textsuperscript{a}, José Julián Estrada\textsuperscript{a}, Ana Sofía Arango\textsuperscript{b}, Paola Sánchez-Zapata\textsuperscript{a}

\textsuperscript{a} Clínica CES, Medellín, Colombia
\textsuperscript{b} Resident of Anesthesiology, Universidad CES, Medellín, Colombia.

Abstract

Background: Hepatopancreatobiliary surgery (HPB) has been able to reduce morbidity and mortality over the past 30 years, as a result of technological breakthroughs, high-volume centers, and the implementation of multidisciplinary groups with fast recovery protocols.

Objective: To compare the impact of implementing fast recovery guidelines in patients undergoing HPB surgery.

Methods: We conducted an observational retrospective study collecting medical records of patients undergoing HPB surgery from July 2012 to January 2017. An analysis was done of the demographic data, frequent diagnoses, fluid therapy, need for transfusions, length of hospital stay, need for reintervention, and 30-day mortality. Two groups were identified: group A (July 2012–December 2014) and group B (January 2015–January 2017) in which fast recovery protocols were implemented.

Results: A total of 364 patients were included, 145 in group A and 219 in group B. The most frequent diagnoses were pancreatic cancer, liver metastasis, cholangiocarcinoma, and bile duct injury. Bleeding was less than 600mL (OR = 12.88, CI 95%: 5.31–31.23)), the transfusion requirements dropped (OR = 0.16; 95% CI: 0.068–0.418), and fluid therapy was below 5000mL in group B (OR = 4.23; 95% CI: 1.76–10.11). Length of hospital stay was 3 days (interquartile range 2–5; \(p<0.001\)), and mortality at 30 days was lower in group B (\(p=0.012\)).

Conclusion: The implementation of fast recovery protocols showed a decrease in intraoperative bleeding, intravenous fluids therapy, length of hospital stay, and 30-day mortality.

Resumen

Introducción: La cirugía Hepatopancreatobiliar (HPB) ha logrado reducir la morbi-mortalidad en los últimos 30 años gracias a avances tecnológicos, centros de alto volumen, implementación de grupos multidisciplinarios y protocolos de recuperación acelerada.

Objetivos: Comparar el impacto en la implementación de guías de recuperación acelerada en pacientes llevados a cirugía HPB.

Métodos: Se realizó un estudio observacional retrospectivo donde se recolectaron historias clínicas de pacientes HPB entre...
Introduction

Since its introduction in 1880, hepatopancreatobiliary surgery (HPB) has been extremely challenging for the surgical team, with a morbidity between 30% and 40%, and a mortality between 5% and 9%.\(^1\) Strategies to reduce perioperative risks and to improve outcomes have been developed over the years. These strategies include advanced management of anesthesia, increasingly specialized diagnostic instruments, enhanced patient selection tools, less invasive surgical techniques, and, above all, enhanced recovery after surgery (ERAS), leading to shorter hospital stays, lower morbidity, and reduced costs.\(^2\)\(^-\)\(^4\)

In our center, a team for the surgical management of these pathologies has been established, with the participation of hepatopancreatobiliary surgeons, hepatobiliary anesthesiologists, nutritional support, intensive care, oncology, and radiology.

In this study, we would like to present our experience through a retrospective analysis of 364 cases of patients undergoing different HPB surgeries, both open and through laparoscopy. The impact of implementing fast recovery protocols was evaluated in terms of intraoperative bleeding, amount of intraoperative fluids, reinter-
vention, hospital stay, and 30-day mortality.

Materials and methods

A retrospective, observational study of cases and controls was conducted, based on a cohort of patients that reviewed individuals undergoing liver, pancreas, and biliary tract surgery by the HPB surgical team, from July 2012 until January 2017. The data collection and analysis was approved by the ethics committee and in accordance with the legal provisions governing the scientific, technical, and administrative standards for healthcare research, as provided for under resolution 8430, this research was considered risk-free.

Two groups were initially identified: Group A comprised the patients operated on between July 2012 and December 2014, and Group B, in whom the fast recovery protocols were implemented between January 2015 and January 2017. Subsequently, a subgroup analysis was conducted, wherein both groups A and B was subdivided into hepatic surgery and pancreatic surgery. For this analysis, any diagnoses of laparoscopic cholecystectomies and other diagnoses with no direct relationship to the pancreas or liver were excluded. All the procedures collected during the study were conducted by the same surgical team, two hepatobiliary surgeons, and two hepatobiliary anesthesiologists (Fig. 1).

The anesthetic management of Group A did not follow any work protocol. All patients were taken to surgery with 8-hour fasting from both solids and liquids, with no carbohydrate loading. No pre-surgical counseling or education was provided. All patients were operated on under general anesthesia; no protocol was used for fluid management based on ad-lib ringer lactate or 0.9% saline solution. The use of vasopressors and the management of analgesia were in accordance with the anesthesiologist criterion.

In the case of Group B, a management protocol was developed using the ERAS society guidelines (www. erassociety.org), from the pre-operative period until patient discharge. This protocol includes nutritionist evaluation 14 days before surgery, to start management with eco-immunonutrition (prebiotics and arginine supplements), pre-anesthetic evaluation providing advice and pre-surgical education, 8-hour fasting for solids and 2 hours for liquids, and the administration of oral carbohydrates (maltodextrins) 2 hours before surgery.

All patients underwent surgery under general anesthesi- anesthesia with an orotracheal tube. Target-controlled infusion balanced anesthesia was administered with remifentanil between 3 and 5ng/ml and sevoflurane to maintain a 0.8 minimum alveolar concentration in the expired gas.

Figure 1. Flowchart of patients.
Source: Authors.
The neuromuscular relaxation was achieved with rocuronium or cisatracurium. The gas flow was adjusted to maintain 70% inspired oxygen fractions. The mechanical ventilation used a tidal volume of 6 to 8mL/kg, the respiratory rate was 12 to 14/minute and positive end expiratory pressure was 5 mm Hg to adjust end tidal CO₂ of 35 mm Hg. In line with the diagnosis and the type of surgery, the decision is made on whether the patient would require central venous catheter monitoring and arterial line. In case of liver surgery, the central venous pressure was kept below 5 mm Hg. The management of fluids below 5000mL, transfusion requirements, higher transfusion needs, and more reinterventions required. The length of hospital stay was shorter in the B-pancreas group and the 30-day mortality was lower (Table 2).

The risk of experiencing bleeding above 600mL was higher in Group A, as well as the need for transfusion and the administration of more than 5000mL of fluid therapy. The hospital stay was shorter in Group B and the 30-day mortality was lower (Table 2).

In the pancreatic subgroup, the risk of bleeding above 600mL was higher in the A-pancreas group, and the need for fluid therapy above 5000mL, higher transfusion needs, and more reinterventions required. The length of hospital stay was shorter in the B-pancreas group (Table 3). Mortality was higher in the B-pancreas group, although the quantitative variables, the median difference was estimated using the Mann–Whitney U test. An alpha value of 0.05 was considered statistically significant.

**Results**

The initial cohort had 364 patients in total, recruited between July 2012 and January 2017. For group A (July 2012–December 2014), 145 patients were identified, and for Group B (January 2015–2017), 219 patients. In the subgroups analysis, 38 patients were classified in the A-pancreas group and 62 patients in the B-pancreas group. In the A-Liver group, 88 patients, and in the B-liver group, 111 patients were allocated. A total of 65 patients were excluded from the total sample, because these patients did not undergo surgical procedures directly associated with the pancreas or liver. **Table 1** shows the demographic data.

The risk of experiencing bleeding above 600mL was higher in Group A, as well as the need for transfusion and the administration of more than 5000mL of fluid therapy. The hospital stay was shorter in Group B and the 30-day mortality was lower (Table 2).

In the pancreatic subgroup, the risk of bleeding above 600mL was higher in the A-pancreas group, and the need for fluid therapy above 5000mL, higher transfusion needs, and more reinterventions required. The length of hospital stay was shorter in the B-pancreas group (Table 3). Mortality was higher in the B-pancreas group, although the quantitative variables, the median difference was estimated using the Mann–Whitney U test. An alpha value of 0.05 was considered statistically significant.

**Results**

The initial cohort had 364 patients in total, recruited between July 2012 and January 2017. For group A (July 2012–December 2014), 145 patients were identified, and for Group B (January 2015–2017), 219 patients. In the subgroups analysis, 38 patients were classified in the A-pancreas group and 62 patients in the B-pancreas group. In the A-Liver group, 88 patients, and in the B-liver group, 111 patients were allocated. A total of 65 patients were excluded from the total sample, because these patients did not undergo surgical procedures directly associated with the pancreas or liver. **Table 1** shows the demographic data.

The risk of experiencing bleeding above 600mL was higher in Group A, as well as the need for transfusion and the administration of more than 5000mL of fluid therapy. The hospital stay was shorter in Group B and the 30-day mortality was lower (Table 2).

In the pancreatic subgroup, the risk of bleeding above 600mL was higher in the A-pancreas group, and the need for fluid therapy above 5000mL, higher transfusion needs, and more reinterventions required. The length of hospital stay was shorter in the B-pancreas group (Table 3). Mortality was higher in the B-pancreas group, although

**Table 1. Demographic data**

<table>
<thead>
<tr>
<th></th>
<th>Group A (n = 145)</th>
<th>Group B or fast recovery (n = 219)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males n (%)</td>
<td>53 (41.1)</td>
<td>76 (58.9)</td>
</tr>
<tr>
<td>Age Me (IQR)</td>
<td>59 (50–70)</td>
<td>57 (48–67)</td>
</tr>
<tr>
<td>ASA n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>2</td>
<td>48 (42.5)</td>
<td>65 (57.5)</td>
</tr>
<tr>
<td>3</td>
<td>92 (37.4)</td>
<td>154 (62.6)</td>
</tr>
<tr>
<td>4</td>
<td>4 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Pancreatic cancer n (%)</td>
<td>31 (21.4)</td>
<td>34 (15.5)</td>
</tr>
<tr>
<td>Liver metastases n (%)</td>
<td>19 (13.1)</td>
<td>18 (8.2)</td>
</tr>
<tr>
<td>Cholangiocarcinoma n (%)</td>
<td>6 (4.1)</td>
<td>22 (10)</td>
</tr>
<tr>
<td>Biliary tract lesion n (%)</td>
<td>15 (10.3)</td>
<td>21 (9.6)</td>
</tr>
</tbody>
</table>

ASA=American Society of Anesthesiologist, IQR=interquartile range. Source: Authors.
the difference between the groups was not statistically significant (P = 0.784) (Table 3).

In the liver subgroup, the risk of bleeding above 600mL was higher in the A-liver group, and fluid requirements above 5000mL were higher, more transfusion requirements, and higher need for reintervention (Table 4). It should be mentioned however that fluid therapy and the need for transfusions showed no statistically significant differences. The hospital stay was shorter in the B-liver group. Mortality was higher in the A-liver group, but the difference among groups was not statistically significant (Table 4).

Discussion

In the 1970s, liver mortality was 20% and was mainly due to bleeding or liver failure. Thanks to the technological breakthroughs of the last few decades, a number of factors have contributed to lower mortality below 5%. Some of these factors include the organization of work teams, centers with high volume of surgeries, laparoscopic surgery, development of techniques for estimating liver volume, and enhanced liver transection techniques using more selective vascular control methods. However, morbidity continues to be around 15% to 35%; thus, optimizing perioperative variables and creating fast recovery protocols are essential to the care of these patients.

Recently, Zhao et al. in their meta-analysis over a 20-year period, found that fast recovery programs in both, open and laparoscopic liver surgery, shorten the hospital stay, reduce the number of complications over 30 days, and lower costs; thus, the authors recommend this strategy as a safe and effective management option.

Furthermore, major pancreatic surgery, despite the technological breakthroughs, continues to show a high morbidity—close to 40%—even at high-volume centers. This is mostly due to pancreatic fistula, bleeding, and delayed gastric emptying. Mortality, which used to be around 30%, has dropped to less than 9%, with the implementation of early recovery protocols and optimiz-

---

**Table 2. Overall results**

|                          | Group A (n=145) | Group B or fast recovery (n=219) | P      | OR (95% CI)  
|--------------------------|-----------------|---------------------------------|--------|--------------
| Bleeding less than 600mL | 13              | 201                             | <0.001 | 12.88 (5.31–31.23) |
| Fluid therapy less than 5000mL | 106           | 211                             | 0.001  | 4.23 (1.76–10.11)   |
| Need for transfusion     | 28              | 8                               | <0.001 | 0.16 (0.068–0.418)  |
| Mortality                | 11              | 6                               | 0.012  | 0.34 (0.12–0.95)    |
| Hospital stay            | 7 (4–14)        | 3 (2–5)                         | <0.001 |              |

CI = confidence interval, OR = odd ratios.
*Chi-square.
†Mann-Whitney U test.
Source: Authors.

**Table 3. Subgroups analysis: pancreas groups**

|                          | Group A-pancreas (n=38) | Group B-pancreas or fast recovery (n=62) | P      | OR (95% CI)  
|--------------------------|-------------------------|------------------------------------------|--------|--------------
| Bleeding less than 600mL | 3                       | 54                                       | 0.001  | 11.25 (2.24–56.4) |
| Fluid therapy less than 5000mL | 23           | 57                                       | 0.001  | 5.94 (1.88–18.78) |
| Transfusion requirement  | 14                      | 2                                        | <0.001 | 0.05 (0.11–0.25)  |
| Reintervention           | 11                      | 6                                        | 0.010  | 0.25 (0.84–0.76)  |
| Mortality                | 3                       | 4                                        | 0.784  | 0.80 (0.17–3.80)  |
| Hospital stay            | 11 (8–17)               | 6 (4–9)                                  | <0.001 |              |

CI = confidence interval, OR = odd ratios.
*Chi-square.
†Mann-Whitney U test.
Source: Authors.
The implementation of these protocols has been able to shorten the hospital stay to lower the incidence of delayed gastric emptying, and reduce costs, without impacting the rate of readmissions, as shown by Xiong et al, in their meta-analysis with 2719 patients undergoing pancreatic surgery.

The ERAS guidelines are based on reducing the surgery-associated stress and hence achieving optimum recovery in a shorter period of time, and at the highest level of quality. This paradigmatic change must involve the creation of multidisciplinary teams, and above all, continuous auditing of the processes to ensure proper compliance with the management guidelines. Around 24 recommendations, spanning from the preoperative period to patient discharge, have been designed for various specialties and procedures.

The preoperative indications include nutritional evaluation and eco-immunonutrition support, optimization of chronic diseases, counseling, and education, that reduces anxiety and improves patient compliance with the protocols, 8-hour fasting for solids and 2-hour fasting for clear liquids, with carbohydrate loading, no intestinal preparation, antithrombotic prophylaxis, and prophylaxis against nausea and vomiting. For the intraoperative period, the recommendation is to use minimally invasive techniques, avoid long-acting opioids, goal-directed fluid management to prevent hypo or hypervolemia, epidural analgesia for open surgery, normothermia and reduced use of drainages, and nasogastric tubes. Early mobilization is emphasized in the postoperative period, in addition to early administration of oral food, early removal of tubes, catheters, drains, and opioid-free multimodal analgesia.

The first published guidelines were for the perioperative management of colorectal surgery; subsequently, some recommendations have been published for major abdominal surgery (rectal resection, cystectomy, gastric resection, major gynecological surgery, bariatric surgery, head and neck surgery, breast reconstruction) including guidelines for pancreaticoduodenectomies in 2012, and guidelines for liver resection in 2016.

The ERAS guidelines based on multimodal strategies have been able to shorten the hospital stay, reduce morbidity, and improve the patient’s function early on. From the anesthetic perspective, these strategies are intended to improve pain control, which leads to early mobilization, better fluid control that starts from the preoperative period with shorter fasting times for fluids and a reduction in the positive balances. Consequently, the patient involved in early recovery programs is discharged earlier, has less medical complications as compared against the standard perioperative treatment groups, and results in lower hospital costs.

One of the key roles of the anesthesiologist is fluid therapy, which should be guided by goals directed at physiological objectives. There must be an awareness of the fact that hyper or hypovolemic conditions increase the risk of perioperative complications. In particular, the type of fluid selected for surgery should be administered when the patient is outside the range of goals to accomplish adequate tissue perfusion and when the patient is a volume-responder, according to the dynamic variables selected under the institutional protocol.

Navarro et al, recommend the use of dynamic variables (SVV, pulse pressure variation, for major surgeries. Our perioperative fluid management protocol is similar to that proposed by Cannesson et al, which includes a basal infusion of balanced solutions and periodic measurement of dynamic variables, associated with a flow-chart that takes into account the heart rate and the mean blood pressure, to decide whether to administer fluid therapy, vasopressors, or inotropes, according to the response.

### Table 4. Subgroup analysis: liver group

<table>
<thead>
<tr>
<th></th>
<th>Group A-liver (n=88)</th>
<th>Group B-liver or fast recovery (n=111)</th>
<th>P</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor bleeding 600mL</td>
<td>9</td>
<td>101</td>
<td>&lt;0.001</td>
<td>11.22 (3.69–34.06)</td>
</tr>
<tr>
<td>Fluid therapy less than 5000mL</td>
<td>67</td>
<td>108</td>
<td>0.170</td>
<td>2.68 (0.62–11.60)</td>
</tr>
<tr>
<td>Transfusion requirement</td>
<td>11</td>
<td>6</td>
<td>0.067</td>
<td>0.39 (0.138–1.10)</td>
</tr>
<tr>
<td>Reintervention</td>
<td>15</td>
<td>3</td>
<td>&lt;0.001</td>
<td>0.13 (0.038–0.48)</td>
</tr>
<tr>
<td>Mortality</td>
<td>6</td>
<td>2</td>
<td>0.074</td>
<td>0.25 (0.49–1.274)</td>
</tr>
<tr>
<td>Length of stay†</td>
<td>6 (4–11)</td>
<td>3 (2–3)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval, OR = odd ratios.
* Chi-square.
† Mann–Whitney U test.
Source: Authors.
Our study has the typical limitations of any observational, retrospective study in which the variables may be subject to information biases, as they are taken from information in the medical records. Likewise, some variables showing clinical outcomes were excluded from the analysis, because the data were not available in the medical record. However, a study analyzing the cost–benefit variables will be extremely valuable for the financial and administrative staff, hence facilitating the investment of economic resources in these programs.

**Conclusion**

The implementation of fast recovery guidelines showed a reduction in bleeding volumes, less intravenous fluids administered, shorter hospital stay, and lower mortality of HPB surgical patients.

**Ethical responsibilities**

Protection of persons and animals. The authors state that no experiments in humans or in animals have been conducted for this research.

Confidentiality of the data. The authors declare that they have followed the protocols of their work institution on the publication of patient information.

Right to privacy and informed consent. The authors declare that no patient data have been disclosed in this article.

**Funding**

The authors declare that no funding has been received.

**Conflicts of interest**

The authors declare that they have no conflicts of interest to disclose.

**References**